WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 4 fonti

Nova injeção elimina completamente hepatite B em 20% dos pacientes

Tratamentos atuais proporcionam cura para apenas cerca de 1% das pessoas que vivem com o vírus de forma crônica

Raccontata daeconomictimes.indiatimes.commorningstar.comindependent.co.ukoglobo.globo.com

Confronto fonti

4 prospettive sulla stessa storia
AI · summaries
oglobo.globo.comStai leggendo6 h fa

Nova injeção elimina completamente hepatite B em 20% dos pacientes

Tratamentos atuais proporcionam cura para apenas cerca de 1% das pessoas que vivem com o vírus de forma crônica

originale
economictimes.indiatimes.com10 h fa

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential…

Leggi questa versione → originale
morningstar.com9 h fa

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to…

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Leggi questa versione → originale
independent.co.uk9 h fa

FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 28 maggio 2026·economictimes.indiatimes.com

    GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

    GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of…

  2. giovedì 28 maggio 2026·morningstar.com

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic…

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

  3. giovedì 28 maggio 2026·independent.co.uk

    FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

    New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

  4. giovedì 28 maggio 2026·oglobo.globo.com

    Nova injeção elimina completamente hepatite B em 20% dos pacientes

    Tratamentos atuais proporcionam cura para apenas cerca de 1% das pessoas que vivem com o vírus de forma crônica